Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00283556
Status:
COMPLETED
Last Update Posted:
2010-01-20
First Post:
2006-01-26
Brief Title:
High Dose Camptothecin-11 CPT-11 in Recurrent Unresectable Malignant Glioma
Sponsor:
Kentuckiana Cancer Institute
Organization:
Kentuckiana Cancer Institute
Study Overview
Official Title:
Phase III Study of High Dose Irinotecan Camptosar CPT-11 in Patients With Recurrent Unresectable Malignant Glioma on SteroidsAnti-epileptics
Status:
COMPLETED
Status Verified Date:
2010-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors
Detailed Description:
This is a phase III study of high dose irinotecan in patients with recurrent unresectable malignant glioma on steroidsanti-epileptics The purpose is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 44OE-ONC-0020-3 | None | None | None |